<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396756</url>
  </required_header>
  <id_info>
    <org_study_id>PLN-74809-IPF-202</org_study_id>
    <secondary_id>INTEGRIS-IPF</secondary_id>
    <nct_id>NCT04396756</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pliant Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pliant Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a, multicenter, 3-part, randomized, double-blind, dose-ranging, placebo-controlled
      study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in
      participants with idiopathic pulmonary fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three part study:

      Part A - 4 week treatment period evaluating PLN-74809 or matching placebo

      Part B - 12 week treatment period evaluating PLN-74809 or matching placebo

      Part C - 12 week treatment period evaluating up to two higher PLN-74809 dose cohorts or
      matching placebo
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A - Number of participants with treatment-related adverse events and laboratory abnormalities, as assessed by CTCAE v5.0</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B &amp; C - Number of participants with treatment-related adverse events and laboratory abnormalities, as assessed by CTCAE v5.0</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PLN-74809 plasma concentrations</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Part A - Assessment of change from baseline in forced vital capacity (FVC)</measure>
    <time_frame>Up to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Part B &amp; C - Assessment of change from baseline in forced vital capacity (FVC)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Part B &amp; C - Change in pulmonary fibrosis score by quantitative HRCT at Week 12</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of change from baseline in a visual analog scale (VAS) scale for cough</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 Dose Level 1 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 Dose Level 1 (Part A) - 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 Dose Level 2 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 Dose Level 2 (Part A) - 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 Dose Level 2 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 Dose Level 2 (Part B) - 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 - Dose Level 3 (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 Dose Level 3 (Part C) - 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 - Dose Level 4 (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 Dose Level 4 (Part C) - 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLN-74809</intervention_name>
    <description>PLN-74809</description>
    <arm_group_label>PLN-74809 - Dose Level 3 (Part C)</arm_group_label>
    <arm_group_label>PLN-74809 - Dose Level 4 (Part C)</arm_group_label>
    <arm_group_label>PLN-74809 Dose Level 1 (Part A)</arm_group_label>
    <arm_group_label>PLN-74809 Dose Level 2 (Part A)</arm_group_label>
    <arm_group_label>PLN-74809 Dose Level 2 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IPF based upon the Fleischner Society guidelines within 3 years from
             Screening (Part A) or based on ATS/ERS/JRS/ALAT 2018 guidelines within 5 years from
             Screening (Part B &amp; C)

          -  FVC %predicted ≥45%

          -  DLco (hemoglobin-adjusted) ≥30%

          -  Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,if
             on a stable dose for at least 3 months

        Exclusion Criteria:

          -  Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents
             not approved for that indication by the FDA

          -  Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC
             ratio &lt;0.7 at Screening

          -  Clinical evidence of active infection, including but not limited to bronchitis,
             pneumonia, sinusitis that can affect FVC measurement or IPF progression

          -  Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months
             of Screening

          -  Smoking of any kind within 3 months of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pliant Therapeutics Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Pliant Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pliant Therapeutics Medical Monitor</last_name>
    <phone>clintrials@pliantrx.com</phone>
    <email>clintrials@pliantrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prinicipal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W1L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

